The generation of anti-tumor immunity in the draining lymph nodes is known as the cancer
immunity cycle. Accumulating evidence supports the occurrence of such a cycle at tumor …

For our immune system to contain or eliminate malignant solid tumours, both myeloid and
lymphoid haematopoietic cells must not only extravasate from the bloodstream into the …

Infiltration of regulatory T (Treg) cells, an immunosuppressive population of CD4+ T cells,
into solid cancers represents a barrier to cancer immunotherapy. Chemokine receptors are …

B cells are a major component of the tumour microenvironment, where they are
predominantly associated with tertiary lymphoid structures (TLS). In germinal centres within …

Although immunotherapy research to date has focused largely on T cells, there is mounting
evidence that tumour-infiltrating B cells and plasma cells (collectively referred to as tumour …

Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …

The accurate identification of antitumor T cell receptors (TCRs) represents a major challenge
for the engineering of cell-based cancer immunotherapies. By map** 55 neoantigen …

Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced
soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary …